8-K: STAAR Surgical Reports Q4 Turnaround, FY25 Losses Amid China Reset

STAAR Surgical reported an 18.1% net sales increase in Q4 2025 and reduced net loss, signaling a turnaround after a challenging fiscal year marked by significant losses and strategic shifts.

Summary

• Net sales for Q4 2025 increased by 18.1% year-over-year to $57.8 million, driven primarily by sales growth in China.
• Net sales for fiscal year 2025 decreased by 23.7% year-over-year to $239.4 million, largely due to distributor and channel inventory reductions in China during the first half of the year.
• The company reported a net loss of $(18.3) million or $(0.37) per share for Q4 2025, an improvement from a net loss of $(34.2) million or $(0.69) per share in the prior year quarter.
• For fiscal year 2025, the net loss was $(80.4) million or $(1.62) per share, compared to a net loss of $(20.2) million or $(0.41) per share in fiscal year 2024.
• Adjusted EBITDA for Q4 2025 was breakeven, a significant improvement from a loss of $(20.8) million in Q4 2024.
• Adjusted EBITDA for fiscal year 2025 was a loss of $(6.6) million, compared to an income of $23.2 million in fiscal year 2024.
• Cash, cash equivalents, and investments available for sale totaled $187.5 million at January 2, 2026, down from $230.5 million at the end of Q4 2024.
• Operating expenses for Q4 2025 included $11.2 million related to the terminated Alcon merger and $0.7 million for restructuring.
• The company repurchased approximately 376,000 shares for $6.5 million under its $30 million share repurchase program, with $23.5 million remaining.
• Warren Foust and Deborah Andrews were appointed interim co-Chief Executive Officers on February 2, 2026, following the termination of the proposed merger with Alcon.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive. While fiscal year 2025 results were significantly negative, the Q4 2025 performance shows a strong positive inflection, coupled with clear strategic actions and an optimistic outlook for 2026, suggesting a potential turnaround.

Positives

• Q4 2025 net sales increased by 18.1% year-over-year to $57.8 million, showing a positive trend after a challenging year.
• Q4 2025 net loss significantly improved to $(18.3) million from $(34.2) million in the prior year quarter.
• Adjusted EBITDA for Q4 2025 reached breakeven, a substantial improvement from a $(20.8) million loss in Q4 2024.
• Net sales excluding China for fiscal year 2025 increased by 6.6% to $161.7 million, demonstrating growth outside the primary challenging market.
• Gross profit margin remained strong at 75.7% for Q4 2025 and 76.2% for FY 2025, indicating efficient cost of goods sold.
• Operating expenses, excluding merger and restructuring costs, decreased by 8.2% in Q4 2025 and 9.4% for FY 2025, reflecting successful cost reduction efforts.
• In-market demand in China showed a mid-single-digit recovery in 2025 and accelerated in Q4, with distributor inventories normalizing.
• The launch of EVO+ ICL in China, manufactured in Switzerland, is expected to drive higher average selling prices and long-term margin expansion, while mitigating US-China tariff volatility.
• FDA expanded EVO ICL's approved age range in the U.S. from 21-45 to 21-60, opening access to nearly eight million additional potential patients.
• Regulatory approval for Taiwan was received in 2025, presenting a new growth opportunity.

Negatives

• Net sales for fiscal year 2025 decreased significantly by 23.7% to $239.4 million compared to $313.9 million in fiscal year 2024.
• The company reported a substantial net loss of $(80.4) million for fiscal year 2025, a significant increase from $(20.2) million in fiscal year 2024.
• Adjusted EBITDA for fiscal year 2025 was a loss of $(6.6) million, a decline from an income of $23.2 million in fiscal year 2024.
• Cash, cash equivalents, and investments available for sale decreased to $187.5 million from $230.5 million at the end of Q4 2024.
• Q4 2025 net sales excluding China decreased by 2.1% to $40.3 million, indicating some weakness in other markets during the quarter.
• Operating expenses for FY 2025 increased to $274.1 million from $252.2 million in FY 2024, primarily due to merger transaction and restructuring costs.
• Uncertainties surrounding the proposed Alcon merger led to lower-than-anticipated Q4 net sales due to sub-distributor and customer inventory returns in China and other regions.

Risks

• Ability to grow and generate profit.
• Reliance on independent distributors in international markets.
• Slowdown or disruption to the Chinese economy.
• Global economic conditions.
• Disruptions in the supply chain.
• Fluctuations in foreign currency exchange rates.
• International trade disputes (including involving tariffs) and substantial dependence on demand from Asia.
• Changes in effective tax rate or tax laws.
• Any loss of use of the principal manufacturing facility.
• Competition.
• Potential losses due to product liability claims.
• Exposure to environmental liability.
• Data corruption, cyber-based attacks or network security breaches and/or noncompliance with data protection and privacy regulations.
• Acquisitions of new technologies.
• Climate changes.
• The willingness of surgeons and patients to adopt a new or improved product and procedure.
• Extensive clinical trials and resources devoted to research and development.
• Compliance with government regulations.
• The discretion of regulatory agencies to approve or reject existing, new or improved products, or to require additional actions before or after approval, or to take enforcement action.
• Laws pertaining to healthcare fraud and abuse.
• Changes in FDA or international regulations related to product approval.
• Product recalls or failures.

Future Outlook

The company is optimistic about 2026, expecting it to be a year of growth, improving profitability, and meaningful progress across its innovation pipeline. It anticipates modest growth in China's in-market volume demand and an increase in net sales due to rising average selling prices for lenses and market share gains, particularly with the EVO+ ICL launch. Management intends to maintain cost discipline as revenue recovers, aiming to return to profitability and eventually achieve double-digit operating margins and substantial revenue growth. The company's core objectives for 2026 are revenue growth, profit expansion, and innovation acceleration.

Management Comments

• "Throughout fiscal 2025, we made meaningful progress on multiple fronts, including rebalancing distributor inventory and disciplined gross profit and expense management. The actions we have taken give us confidence in a clear path toward sustained profitability and growth, and we are optimistic about the business in 2026."
• "In 2026, with the merger question behind us, we believe we will see modest growth in in-market volume demand and expect net sales in China to increase due to rising average selling prices (ASPs) for lenses and market share gains."
• "STAAR possesses a differentiated proprietary material with Collamer, exceptional optical technology with EVO ICLs, and a proven ability to gain market share. With a large addressable market opportunity driven by the increasing prevalence of myopia worldwide, our leadership in lens-based refractive surgery provides us with a winning formula."
• "2025 was a difficult year of transition for STAAR. We expect 2026 to be a much better year, a year of growth, improving profitability, and meaningful progress across our innovation pipeline."
• "As co-CEOs, our partnership is rooted in complementary experience, shared values, and a unified commitment to long-term value creation. We believe this structure enhances decision-making, deepens operational oversight, and positions us to move with both agility and discipline."

Industry Context

StockSavvy.ai notes that STAAR Surgical, as the global leader in phakic IOLs, is positioned within an ophthalmology market that is increasingly shifting towards lens-based refractive surgery, moving away from traditional laser-vision correction procedures that remove corneal tissue and can contribute to dry eye disease. The global epidemics of myopia and dry eye disease continue to drive demand for solutions like EVO ICL. The U.S. refractive market for laser-based procedures has been in decline since 2018, with an accelerated double-digit decline since 2022, highlighting the potential for lens-based alternatives to gain market share. In China, despite past macroeconomic headwinds and consumer spending volatility, in-market demand for EVO ICL is recovering, supported by government stimulus and a return to growth for global luxury brands by late 2025, suggesting improving consumer confidence for premium procedures. Refractive surgery penetration in China remains low despite high myopia rates, indicating significant long-term growth potential, mirrored by emerging opportunities in other Asian markets like India.

Comparison to Industry Standards

• EVO ICL has grown to represent an estimated 12% of refractive surgeries globally, indicating a strong position in the overall refractive market.
• The U.S. refractive market for laser-based procedures has declined at double-digit rates since 2022, and has been in decline since 2018 (excluding the temporary post-COVID rebound in 2021), with the rate of decline accelerating from approximately 8% to nearly 20%. This contrasts with STAAR's reported respectable growth in the U.S. for EVO ICL, suggesting market share gains against laser-based competitors.
• Refractive surgery penetration in China remains well below that of many developed markets, despite China having one of the highest rates of myopia in the world, highlighting a significant untapped market opportunity for STAAR compared to more mature markets.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Experienced significant net losses for FY 2025, but Q4 2025 showed improvement. The termination of the Alcon merger and new leadership aim to refocus on long-term value creation. A share repurchase program is in place.
• Customers (Distributors/End-users): Faced uncertainty and returned inventory due to the Alcon merger proposal, impacting Q4 sales. However, inventory normalization and new product launches (EVO+) are expected to improve future sales and product availability.
• Employees: Leadership changes with interim co-CEOs and new SVP appointments in supply chain and APAC. Cost reduction programs were implemented in early 2025, which could impact employees.
• Regulatory Authorities: FDA expanded EVO ICL age range in the U.S., and regulatory approval for EVO+ in China and EVO ICL in Taiwan were achieved, indicating continued compliance and market access.

Next Steps

• Conduct a search for STAAR's next Chief Executive Officer, including both internal and external candidates, led by Egon Zehnder.
• Accelerate adoption of EVO+ ICL in China by working closely with distributor partners.
• Continue efforts to improve tracking of channel inventory in China during 2026.
• Expand efforts in the Taiwan market in 2026 and beyond following regulatory approval.
• Provide updates on progress in the development pipeline throughout 2026.
• Focus on three core objectives for 2026: Revenue Growth, Profit Expansion, and Innovation Acceleration.

Key Dates

Recommendation

While STAAR Surgical reported a challenging fiscal year 2025 with significant losses, the fourth quarter showed notable improvements in sales growth, reduced net loss, and breakeven Adjusted EBITDA. The termination of the Alcon merger and the appointment of new interim co-CEOs, coupled with strategic initiatives like China inventory normalization, Swiss manufacturing expansion, and new product launches (EVO+), position the company for a potential turnaround in 2026. However, the full-year performance indicates substantial headwinds that still need to be overcome. A 'hold' recommendation is appropriate as investors should monitor the execution of the stated 2026 objectives, particularly revenue growth and profitability expansion, before committing to a stronger position.

Keywords

STAAR Surgical, STAA, EVO ICL, Phakic IOLs, Vision Correction, Ophthalmology, Refractive Surgery, Myopia, China Market, Financial Results, SEC Filing, Earnings, Medical Devices, Collamer Lenses